Immunovant, Inc. - IMVT

SEC Filings Our IMVT Tweets

About Gravity Analytica

Recent News

10.21.2026 - Immunovant to Report Financial Results for the Second Fiscal Quarter Ended September 30, 2026, and Provide Business Update on Monday, November 9, 2026
09.23.2026 - Immunovant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus
08.06.2026 - Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2026
07.23.2026 - Immunovant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026
05.20.2026 - Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026
05.11.2026 - Immunovant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026, and Provide Business Update on Wednesday, May 20, 2026
04.02.2026 - Immunovant Announces Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED)
02.06.2026 - Immunovant Provides Corporate Updates and Reports Financial Results for the Third Quarter Ended December 31, 2025
01.23.2026 - Immunovant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026
12.11.2025 - Immunovant Announces Pricing of $550 Million Common Stock Financing

Recent Filings